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Abstract: Cutaneous melanoma (CM) is an aggressive type of skin cancer for which effective biomarkers 
are still needed. Recently, the protein content of extracellular vesicles (ectosomes and exosomes) became 
increasingly investigated in term s of its functional role in C M  and as a source of novel biom arkers; 
however, the data concerning the proteom e of CM -derived ectosom es is very limited. We used 
the shotgun nanoLC-MS/MS approach to the profile protein content of ectosomes from primary (WM115, 
W M 793) and metastatic (W M266-4, W M 1205Lu) CM  cell lines. Additionally, the effect exerted by CM  
ectosomes on recipient cells was assessed in terms of cell proliferation (Alamar Blue assay) and migratory 
properties (w ound healing assay). A ll cell lines secreted heterogeneous populations of ectosomes 
enriched in the com m on set of proteins. A  total of 1507 unique proteins w ere identified, w ith m any of 
them  involved in cancer cell proliferation, m igration, escape from apoptosis, epithelial-m esenchym al 
transition and angiogenesis. Isolated ectosom es increased proliferation and m otility of recipient cells, 
likely due to the ectosomal transfer of different cancer-promoting molecules. Taken together, these results 
confirm  the significant role of ectosom es in several biological processes leading to C M  developm ent 
and progression, and m ight be used as a starting point for further studies exploring their diagnostic 
and prognostic potential.
Keywords: biom arkers; cutaneous melanoma; ectosomes; extracellular vesicles; invasion; metastasis; 
proteom ics
1. Introduction
Cutaneous m elanom a (CM) is the m ost aggressive type of skin cancer, and its incidence is increasing 
rapidly w ith approximately 350,000 new cases worldwide each year [1]. C M 's growing prevalence has 
increased the necessity  for research into im proved diagnostic, preventative and treatm ent m ethods; 
however, early detection and disease constraint still present significant challenges.
As successful isolation protocols developed, extracellu lar vesicles (EVs) becam e w idely 
investigated in term s of their functional role in C M  and as a possible source of d isease biom arkers.
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Viable cells predom inantly  release tw o types of EVs: ectosom es, directly shed from  the plasm a 
m em brane, and exosom es, released after fusion of m ultivesicu lar bodies (M VBs) w ith  the plasm a 
membrane. In the case of apoptotic cells, cell fragmentation and formation of apoptotic bodies, the third 
type of EV, containing nuclear and cytoplasm ic m aterial as w ell as intact organelles, is observed [2]. 
The specific content of EVs and their action tow ards recipient cells depend on their m olecular 
com position, w hich  is determ ined by  the cell o f their origin. Proteins, lipids and/or nucleic acids 
specific for a given cell type can be detected in EVs after their isolation from body fluids or conditioned 
m edia [3 ]. Such accessibility of EVs contributes to their prognostic and diagnostic value and indicates 
their potential as an alternative to invasive biopsy procedures.
C om pared w ith  extensive research on m elanom a-derived  exosom es [4,5 ], ectosom es appear 
as an understudied population of EVs, though their tum or-prom oting activity  has already been 
recognized. Ectosomes were shown to modulate extracellular matrix degradation during CM invasion 
and m etastasis [6- 8], tissue factor (TF)-related procoagulant state [9], tum or-strom a interactions [10], 
as w ell as suppression of im m une response [11] .
Besides functional studies, qualitative and quantitative proteom ics em erged as a m ajor tool for 
the identification of particular m olecules w ithin ectosom es, w hich account for their tum or-prom oting 
activity. D ue to the h igh throughput and sensitivity of m ass spectrom etry, the num ber of proteom ic 
EV-oriented studies are constantly increasing and creating alternative analytical approaches, such as 
gel-based or shotgun proteom ics. N ovel, state-of-the-art m ethods allow  identification of over 1000 
proteins in one EV sample originating from different m elanom a cell lines and solid melanoma tumors [5 ].
Nevertheless, the amount of data concerning the proteome of CM -derived EVs is still very limited. 
Considering the potential role of EVs in the development and progression of CM , the present study uses 
a nanoLC-M S-based proteomic approach to investigate the protein content of ectosomes derived from 
two prim ary and metastatic CM cell lines. In addition, cancer-promoting effects exerted by CM-derived 
ectosom es on equally  or less invasive recipient cells in  term s of cell proliferation and m igratory 
properties w ere assessed.
2. Results
2.1. Size and M arker Characterization o f  CM  Ectosomes
In the present study, ectosome isolation based on sequential centrifugation with final centrifugation 
at 18,000x g  w as applied. Transm ission Electron M icroscopy (TEM ), N anoparticle Tracking Analysis 
(NTA) and W estern B lot (W B) w ere perform ed to validate the sam ple purity  and effectiveness of 
isolation. U ltrathin  TEM  sections of ectosom e sam ples derived from  four C M  cell lines contained 
num erous, d istinguishable vesicles (Figure 1A ). The observed populations w ere heterogeneous 
and contam inated neither w ith  cells nor w ith cellular organelles. Regarding particle size, only a few 
vesicles smaller than 100 nm or larger than 1 gm in diameter were found (Figure 1A ). Ectosome samples 
w ere sim ultaneously  analyzed by NTA (Figure 1B ). The obtained results confirm ed that a m ajority  
of vesicles w ere larger than 100 nm , proving contam ination w ith  exosom es negligible. M oreover, 
according to both  TEM  and NTA m easurem ents, ectosom es w ith  a d iam eter range of 100-300  nm  
constituted the m ost abundant subpopulation of ectosomes in each sample. Additionally, the absence or 
depletion of classical exosomal protein m arkers, CD63 and Hsp70, was demonstrated for each ectosome 
sample (Figure 1C ). In contrast, ectosome samples were enriched in ARF6, the protein involved directly 
in the shedding of plasm a m em brane-derived EVs but not in exosom e biogenesis. Based on the above 
evidence, w e considered the isolated EV  population to be highly enriched in ectosom es.
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Figure 1. Analysis of ectosome sample purity. (A) TEM analysis of cutaneous melanoma (CM)-derived 
ectosomes. Size distributions are presented on histograms. Mean diameter ± standard deviation was 
calculated for rll observed vesicles (n) from a given sample. (B) Nanoparticle Tracking Analysis (NTA) 
analysis of CM-derived ertosomes. Results fromfive independent measurements for each CM cell 
line are presented on graphs. The shaded area depicts standard deviation. (C) Western blot analysis 
o!F extracellular vesicle (EV) markers. Fifty |g of proteins from whole-cell pcotein extracts (lmes C) 
and ectosome samples (lines E) separated by 10°% SDS-PAGE and transferred into PVDF membrane 
were probed with snti-CD63 (1:200)0), anti-HSP70 (1:2b00) and anti-ARF6 (1:500i as primary antibodies 
and anti-mouse IgG-HRP (1:400) as a secondary antibody. WM115 (primary) end WM266-4 (metastatic), 
cell lines originating from the same individual, radial/vertifat growth phaae and lymph node metastasis, 
respectively; primary WM793 cell line, representing the vertical growth phase; WM1205Lu, a metastatic 
veriana oC WM793 cells obtained lrom lung metastasis.
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2.2. Identified Proteins o f  CM  Ectosomes and Their Functional Classification
Protein  profiles for ectosom es secreted by  four C M  cell lines w ere obtained using the gel-free 
nanoLC-M S/M S proteom ic approach. For all cell lines, a total o f 1507 unique proteins (listed in 
Supplem entary  M aterials D ata 1) w ere identified in  tw o biological replicates and w ith  at least tw o 
peptides. R egarding particular cell lines, ectosom es from  m etastatic W M 793 cells had the highest 
num ber of 1055 proteins, w hile ectosom es from metastatic W M 266-4 cells had the lowest num ber of 936 
proteins (Figure 2A ). In all ectosomal samples, 576 proteins were present, while the num ber of proteins 
unique for a given cell line ranged betw een 78 (primary W M 115 cells) and 173 (primary W M 793 cells). 
Moreover, a com parison to the Vesiclepedia database w as made (Figure 2F) for each ectosom e sample. 
Tire vast m ajority of proteins identified by the present study were also detected by other vesicle-rolated 
studies, supporting their vesicular origin instead of being a part of co-isolated cell debris, etc.
Figure 2. (A) Number of proteins identified in two biological replicates of each CM ectosome sample 
by at leftist two peptides. (B) Venn diagram illustratino the; number of proteins shared between given 
ectosome samp les. (C) Percentage of proteins shared between given ectosome; sa mples. Venn diagrams 
illustrating the number of proteins shared between ectosomes released by isogenic (D) and primary;
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or metastatic CM cells (E). Venn diagram illustrating protein overlap between CM ectosomes 
and Vesiclepedia database as a reference (F). Ectosomes were isolated from WM115 (primary) 
and WM266-4 (metastatfc) cell lines originating; from the same individual, radial/vertical growth 
phose and lymph node metastosts, respectively; primary WM793 cell line, representing vertical growth 
phase; and WM1205Lu, a metastatic variant of WM793 cells obtained from lung metastasis.
Su9 sequentlg, Gene Ontology (GO) analysis was performed to group identified proteins accordmg 
to the cellular com partm ents oe their origin, moleculor functions and invulvement fn (Efferent biological 
proeesees. For each cell fine, the largest group of ectosom al proteins wos associated w ith  cytosolic 
(up to 59.5 % of identified protiins) or m em brane origin (up to 40.2%, Figu re 3A ). This finding reflects 
the m hchanism  of ectosom e biogenesis w hich  involves ehe accum ulation of their com ponents in 
particular dom ains w ifhin  the m em branes of nrigin. In support of the p lasm a m em branh origin  of 
ectos.m es, many of tire identified proteins w ere associated w ith cell-ceh  ad hesion inclu ding; adherent 
junctions (up to 15.8%.) and focal adhesion (up) to 21.50%). Mosoover, approximately7 60% of proteins from 
each ectosom gl sam ple w ere related to m elanoiom es, reflecting the m elanocytic origin of CM  cells.
Figure 3. Gene ontology (GO) analysis of CMS ectos omal proteins from four different cell lines performed 
with the use of FunRich 2 . 0 software with UniProt fleleahe 2019_11) detabase as a reference. For each
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GO term ("Cellular compartment" (A), "Molecular function" (B), "Biological process" (C)), six categories 
with the highest statistical significance of protein enrichment within the specific category (p < 0.001) 
were presented on graphs. Ectosomes were isolated from WM115 (primary) and WM266-4 (metastatic) 
cell lines originating from the same individual, radial/vertical growth phase and lymph node metastasis, 
respectively; primary WM793 cell line, representing vertical growth phase; and WM1205Lu, a metastatic 
variant of WM793 cells obtained from lung metastasis.
R egarding m olecular functions (Figure 3B), the m ost abu ndant groups of proteins w ere 
related to cadherin  binding during ce ll-ce ll adhesion, b inding of RN A  and signal transduction. 
Particularly, nucleotide-binding proteins were w idely represented alongside proteins involved in W nt, 
TN F-m ediated or M APK signaling pathways. Annotations related to biological processes (Figure 3C ) 
revealed the enrichm ent in proteins involved in translation and co-translational processes such as RNA 
m etabolism /processing and protein targeting. Strikingly, none of the aforem entioned classifications 
show ed noticeable differences betw een sam ples, suggesting that the ultim ate role of the ectosom al 
proteom e for CM  cells in in vitro culture w as sim ilar for all CM  cell lines.
To gain insight into how  recip ient cells could be im pacted  by  C M  ectosom es during cancer 
progression, selected cancer-related G O  categories and a num ber of protein annotations w ere 
presented on the heat m ap (Figure 4 ). C ategories w ith  the highest num bers o f annotated proteins 
included TN F-m ediated signaling, cell proliferation, negative regulation of apoptosis, cell m igration 
and angiogenesis, reflecting the cancer-prom oting effect of C M  ectosom es (Figure 4 ). M oreover, 
the percentage of annotations for analogous categories w as com pared betw een the lists of proteins 
from all and only m etastatic CM  ectosom e sam ples (Figure 5 ). The percentage of proteins assigned to 
the m ajority of chosen categories was higher for ectosomes from metastatic cell lines, w hich corresponds 
to their m ore aggressive phenotype.
W hen  com paring only differential proteins from  W M 115 and W M 793 ectosom es, G O  analysis 
indicated that ectosom es isolated from  W M 115 cells are better equipped w ith  proteins involved in 
transport, especially the proteins related to vesicle-m ediated transport (Supplementary M aterials Data 
2, Figure S1). Additionally, M H C  class II receptor activity  G O  category  w as enriched for W M 115 
ectosomes when compared with ectosomes derived from W M 266-4 cells (Supplementary M aterials Data 
2, Figure S2), which is in line w ith the results of comparative transcriptome studies of M HC-II expression 
in these cell lines [12]. The com parison betw een W M 793 and W M 1205Lu ectosom es revealed that 
W M 793 ectosomes carry more proteins involved in im m unity regulation, w hile W M 1205Lu ectosomes 
com prise m ore proteins that regulate m igration, localization and adherent junction  (Supplem entary 
M aterials D ata 2, Figures S3 and S4). Finally, the com parison betw een ectosom es obtained from  tw o 
m etastatic cell lines, W M 266-4 and W M 1205Lu, show ed that W M 1205Lu ectosom es contain m ainly 
proteins of M H C -I com plex, w hile W M 266-4 ectosom es contain  both M H C -I and M H C -II proteins 
(Supplem entary M aterials D ata 2, Figures S5 and S6).
In  sum m ary, ectosom es obtained from  tw o independent isogenic m elanom a m odels (prim ary 
tum or vs. m etastasis w ithin  one donor) W M 115/W M 266-4 and W M 793/W M 1205Lu cell lines w ere 
used to assess w hether their cellular origin (skin or lym ph node/lung m etastasis) affect their overall 
m olecular com position and function. However, regardless of their origin (corresponding to different 
disease stages), C M  ectosom es displayed an alm ost identical pattern of enrichm ent w ithin  the m ost 
abundant G O  categories, w hich  is likely  related to the com m on p art of their proteom e, i.e., 576 of 
shared proteins (Figure 2B). Proteins unique for C M  ectosom es from  given cell line do not, therefore, 
appear to affect basic processes and molecular functions mediated by vesicles; nevertheless, they might 
be responsible for their cancer-prom oting effects.
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Figure 4. Gene ontology annotations by the biological process for each CM ectosome sample performed 
with the? use of FunRich 2.(3 software via UniProt (release 2019_11) database. Numbers of proteins within 
the chosen cancer-related categoriea (wiah statistiiFl significance of protein enrichment within the given category 
calculated as -log10(p value)) are shown on the heat map. Ectosomes were isoloted from WM115 (primary) 
and WM266-4 (metastatic) cell lines originating from the same individual, radial/vertical growth phase and lymph 
node metastasis, respectively; primary WM793 cell line, representing vertical growth phase; and WM1205Lu, 
a metastatic variant of WM793 cells obtained from lung metastasis.
Figure 5. Gene ontology annotations by/" the biological process for each CM ectosome sample performed 
via UniProt (release 2019_11) database. Percentages of proteins within the chosen cancer-related
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categories for ectosomes from all or metastatic cell lines are presented on the graph. Ectosomes 
were isolated from WM115 (primary) and WM266-4 (metastatic) cell lines originating from the same 
individual, radial/vertical growth phase and lymph node metastasis, respectively; primary WM793 cell 
line, representing vertical growth phase; and WM1205Lu, a metastatic variant of WM793 cells obtained 
from lung metastasis.
2.3. Cancer-Prom oting Effect o f  Ectosomes D erived from  M etastatic Cells on Less Invasive Cells
In connection with the presence of multiple cancer-promoting factors demonstrated by proteomics, 
functional tests w ere perform ed to prove that proteins carried by  ectosom es indeed m odulate 
the function of recipient cells. It was evaluated whether self-derived ectosomes and ectosomes released 
by  isogenic m etastatic cells exert a cancer-prom oting functional effect on W M 115 and W M 793 cells. 
In w ound healing assay, the addition of either W M 266-4- or W M 1205Lu-derived ectosom es (30 gg 
or 60 gg of protein) increased the m otility  of recipient cells (Figure 6) . In the case of W M 115 cells, 
the velocity of wound closure was similarly 1.5-2.5 times higher in com parison to the control, regardless 
of w hether the cells w ere treated w ith W M 115 or W M 266-4 ectosom es. W hen ectosom es w ere added 
to W M 793 cell culture, a dose-dependent increase in w ound closure w as observed, w ith W M 1205Lu 
ectosom es causing significantly higher response at corresponding doses.
Figure 6. Cont.
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Figure 6. Effect exerted by self-derived ectosomes and ectosomes released by their isogenic metastatic 
cells, on the motility of primary WM115 and WM793 cells. Wound healing assay was performed after 
18 h of incubation with ectosomes. (A) Representative images were taken at 0 h and at 18 h. (B) Graphs 
presenting relative velocity of wound closure calculated from three repetitions. denotes statistically 
significant differences (Tukey's post-hoc test, p value < 0.05).
Additionally, Alam ar Blue cell viability assay was carried out to assess ectosome-induced changes 
in melanoma cell proliferation rate (Figure 7). After incubation with W M 266-4- and W M 1205Lu-derived 
ectosomes (30 pg or 60 pg of protein), higher fluorescence of recipient cells was measured in comparison 
to the untreated control. In the case of ectosom es derived from  prim ary CM  cells, W M 115 ectosom es 
exerted a sim ilar effect on recipient cells as their m etastatic equivalent (W M 266-4 ectosom es), bu t 
W M 793 ectosom es caused a lower increase in cell viability than W M 1205Lu ectosomes. The observed 
effects were dose-dependent. To sum up, wound healing and proliferation assays proved that proteins 
carried by  ectosom es derived from  CM  cells indeed m odulated the function of recipient cells.
Figure 7. Effect of incubation with self-derived ectosomes and ectosomes released by their isogenic 
metastatic cells, on proliferation of primary WM115 and WM793 cells. Alamar Blue assay was carried 
out after 18 h of incubation with ectosomes. All experiments were conducted in triplicate. denotes 
statistically significant differences (Tukey's post-hoc test, p value < 0.05).
3. D iscussion
3.1. Proteins Involved in Cancer Progression Detected in CM -derived Ectosomes by LC-M S/M S
In the present study, ectosom es w ere isolated from  conditioned m edia of in vitro cultured four 
CM cell lines representing different stages of tire disease. Sequential centrifugation w ith the final step
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at 18,000x g  w as applied to pellet ectosom es. The range betw een 16,000 and 20 ,000x  g  is considered 
to be sufficient for successful isolation of ectosom es, bu t insufficient for pelleting exosom es (at least 
approx. 100,000x g  is required). Similar centrifugal forces can also be applied to pellet apoptotic bodies; 
how ever, viable m elanom a cells in culture should not release apoptotic bodies if apoptotic processes 
are not over-induced [13]. Since sequential centrifugation is based on the differences in  the size of 
isolated particles, it is biased by the size overlap betw een EV subpopulations. Therefore, isolated EV 
populations should rather be analyzed in term s of their relative depletion or enrichm ent. Herein, w e 
showed, using three independent methods, i.e., TEM, NTA and W estern Blot, that isolated EV samples 
w ere highly enriched in ectosom es. The m ajority of isolated vesicles w ere w ithin the predefined size 
range for ectosomes, depleted of exosomal markers (CD63 and Hsp70), and enriched in ARF6, a protein 
m arker confirm ing plasm a m em brane origin of EVs.
O btained ectosom e sam ples from  prim ary (W M 115, W M 793) and m etastatic (W M 266-4, 
W M 1205Lu) C M  cell lines w ere next analyzed using the shotgun nanoLC-M S/M S approach to 
profile their protein content. GO analysis for CM ectosomes revealed the presence of proteins involved 
in cell proliferation, m igration, escape from apoptosis, angiogenesis, etc., and m ost proteins belonging 
to these groups w ere m ore abundant in ectosom es released by m etastatic C M  cell lines. M oreover, 
the functional tests performed in the present study have shown that ectosomes stimulated proliferation 
and m igratory properties of recipient m elanom a cells, m ost likely  due to the ectosom al transfer of 
different cancer-prom oting m olecules.
R egard ing the altered adhesion and m otility  of C M  cells, the action of integrins and cadherins 
has been  w idely  studied. Increased expression of integrin a v p 3  correlated w ith  the progression of 
melanoma from radial to vertical growth phase [14], while expression of integrins a2p1 and a3p1 was 
increased in metastatic cells compared to primary ones [15,16]. Additionally, the restored expression of 
E-cadherin w as found to inhibit m elanom a cell invasion by decreasing the expression of p3 integrins 
and M UC18 receptor [17]. In the present study, all the aforementioned integrin subunits were identified 
in each ectosom e sam ple together w ith  a 4 , a5 , a 6  integrin  subunits and M U C 18. O ther integrin 
subunits, i.e., a1 , p5 and p8, w ere present in three sam ples, w hereas a 9  integrin subunit w as found 
only in ectosom es derived from m etastatic W M 266-4 cells.
Dissem ination of cancer cells is also highly dependent on the activity of matrix metalloproteinases 
(M M Ps). C M  ectosom es have already been  show n to facilitate the transfer of M M P-1, M M P-2 
and M M P-9 and their endogenous activator C D 147 [6- 8,10]. In the present study, the num ber of 
proteins involved in  m atrix disassem bly  w as higher in  ectosom es derived from  prim ary C M  cells; 
however, M M P-14 w as the only M M P identified in each sample. In contrast, CD147 w as present in all 
sam ples, suggesting that C M  ectosom es m ay n ot alw ays transfer M M Ps, bu t have a regulatory role 
towards the activity of M M Ps that are already present.
N oticeably, several m arkers of ep ithelial-m esenchym al transition (EM T) w ere present in CM  
ectosom es including N-cadherin and vim entin. Overexpression of N -cadherin in prim ary m elanom as 
and the loss of E-cadherin  expression in prim ary m elanom as and m etastatic m elanom as correlated 
w ith  w orse overall survival of C M  patients [18]. The absence of E-cadherin  and the presence of 
N -cadherin in C M  ectosom es m ay reflect their potential to induce or prom ote EM T in recipient cells 
and such properties have already been  show n for exosom es released by bladder cancer cells [19] 
and exosom es from plasma of breast cancer patients [20]. Additionally, Qendro et al. [4] demonstrated 
that the pattern of vim entin expression in exosom es can help predict tumor aggressiveness in different 
subtypes of m elanom a.
Furtherm ore, ectosom es facilitate the transfer of proangiogenic factors or up-regulate their 
expression in endothelial cells [21- 23]. In the present study, comparable numbers of angiogenesis-related 
proteins w ere identified in all ectosom e sam ples, including proteins involved in vascular endothelial 
growth factor (VEGF)-mediated signaling. Nevertheless, VEGF was not found in any sample and only 
ectosom es from  prim ary W M 793 cells carried V EG F receptor 1 (VEGFR1). In addition, neuropilin 1,
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another VEGF receptor that integrates proangiogenic signals, w as present in ectosomes from metastatic 
W M 1205Lu cells.
Cancer progression is also associated w ith a prothrom botic state. In the studies by Lim a et al. [9], 
m elanom a-derived  ectosom es displayed a greater procoagulant activity  (resulting from  elevated 
levels of tissue factor (TF)) than m elanocyte-derived ectosom es. A  m ore recent study show ed that 
accum ulation of pancreatic cancer-derived ectosom es at the site of throm bosis is m ediated by avp 1 
and a v p 3  integrins [24], both  identified in each ectosom e sam ple in the present study. A lthough w e 
did not identify  TF in any C M  ectosom e sam ple, other procoagulant m olecules such as urokinase 
plasm inogen activator receptor (uPAR), tissue plasm inogen activator (tPA) and plasm inogen activator 
inhibitor type 1 (PAI-1) w ere present in ectosom es from  isogenic prim ary W M 793 and m etastatic 
W M 1205Lu cells. In addition, PAI-2 w as identified in W M 793 ectosom es. Its absence in  W M 1205Lu 
ectosomes m ay reflect the prim ary origin of W M 793 cells, since PAI-2 was previously shown to inhibit 
uPA activity in less invasive tum ors in a m ice m elanom a m odel [25] .
M oreover, in the present study, ectosom es of m etastatic origin  had a higher percentage 
of proteins associated w ith  negative regulation of the apoptotic process, including annexins or 
program m ed cell death protein 10 (PD CD 10). Furtherm ore, T-cadherin (cadherin-13) w as identified 
in W M 793 and W M 1205Lu ectosom e sam ples. Bosserhoff e t al. [26] have already dem onstrated in 
m ice that the grow th of T -cadherin-positive m elanom a tum ors w as d im inished in com parison to 
T-cadherin-negative control, suggesting that loss of T-cadherin desensitizes m elanom a cells to apoptosis.
Tum or-derived EVs are associated w ith  suppression of im m une response tow ards transform ed 
cells, for instance, by inducing chem otaxis of blood leukocytes [27]. In the present study, CM ectosomes 
carried several m olecules involved in leukocyte m igration such as L1 cell adhesion m olecule (L1CAM) 
and integrins. In a study by  Valenti e t al. [28], CM  ectosom es inhibited differentiation of m onocytes 
to antigen-presenting dendritic cells and the rem aining m onocytes released transform ing grow th 
factor p (TGF-p), which inhibited T-cell cytolytic activity. CM  ectosom es w ere also shown to suppress 
the im m une response by vesicle-associated  Fas (FasL) and TR A IL ligands [11]. O ur C M  ectosom e 
sam ples did not contain any of the aforem entioned m olecules; however, m ultiple proteins involved in 
T-cell response were identified, including com ponents of major histocom patibility com plex I (MHC I). 
R em oval of M H C  I m olecules v ia  ectosom es m ay lead to the loss o f tum or recognition by cytotoxic 
T-cells, and m ay lim it the efficacy of cancer im munotherapy.
C ancer cells have also been  show n to overexpress different transporter proteins involved in 
m ultidrug resistance (M DR) and the efflux of anticancer drugs, i.e., P-glycoprotein (Pgp), m ultidrug 
resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) [29]. In the present 
study, MRP1 w as present in ectosom es released by three CM  cell lines (besides W M 793) and previous 
studies by  W alsh et al. [30 ] show ed an association of h igher M RP1 levels in biopsy  specim ens w ith  
aggressiveness and spread of m etastatic m elanom a.
3.2. M elanom a-D erived Ectosomes as a Source o f  Potential D isease Biomarkers
O ver the years, a num ber of potential m arkers for C M  have been  investigated. H ow ever, only 
a few  of them  have been recom m ended for clinical practice, such as lactate dehydrogenase (LD H ) or 
S100B protein, but their poor sensitivity and specificity are major limitations for routine use. The serum 
levels of S100B, which was found in all CM ectosome samples in the present study, is linked to the tumor 
burden and reflects a clinical stage of CM . It is not, how ever, a good indicator of treatm ent response 
for patients w ith stage I, II and III C M , but it is still used as a biom arker for m onitoring patients w ith 
advanced m etastatic d isease only [31,32]. In  the present study, all C M  ectosom e sam ples contained 
also LDH, the elevated serum level of w hich is used as an independent and highly significant predictor 
of survival in CM  [33] .
The m elanom a biom arker field recently saw  advancem ents by  different proteom ic strategies. 
Findeisen et al. [34] used m atrix-assisted laser desorption/ionization tim e-of-flight m ass spectrom etry 
(M A L D I-T O F-M S) and show ed that serum  am yloidal protein (SA A ) and c-reactive protein (CRP)
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could serve as prognostic serum  biom arkers for early-stage C M  patients. The sam e technique w as 
applied for com parative analysis of C M  specific spots after tw o-dim ensional gel electrophoresis 
that revealed five potential biom arkers, i.e., eukaryotic elongation factor 2, enolase 1, aldolase A, 
glyceraldehyde-3-phosphate dehydrogenase and heterogeneous nuclear ribonucleoprotein A2/B1 [35]. 
A similar study identified six more proteins overexpressed in m elanom a cell lines compared to normal 
m elanocytes, i.e., galectin-1, inosine-5 '-m onop hosphate dehydrogenase 2, serine/threonine-protein 
phosphatase 2A 65 kDa regulatory subunit A a  isoform , protein DJ-1, cyclophilin A and cofilin-1 [36].
Stable isotope labeling w ith am ino acids in the cell culture (SILA C ) before M S analysis provides 
further advantages in  biom arker-focused proteom ic studies. The peptide peaks of the differentially 
labeled samples can be accurately quantified relative to each other to determine the peptide and protein 
ratios. Using SILAC, Liu et al. [37] detected differential expression of CUB-dom ain-containing protein 
1 (CD CP1) in plasm a m em brane proteom e of tw o C M  cell lines of low  and h igh m etastatic potential. 
Sim ilar SILA C -based proteom ic com parison of prim ary W M 115 and m etastatic W M 266-4 cell lines 
indicated changes in cyclophilin A  expression related to the disease stage [38]. Finally, the m etastatic 
potential of CM cells was also correlated by proteomic studies w ith expression levels of annexin 1 [39], 
nucleophosm ine- and hepatom a-derived grow th factor (H D G F) [40] .
O nly  five of the aforem entioned proteins (SA A , CRP, C D C P1, H D G F and cyclophilin  A) have 
not been  detected in  C M  ectosom es in the present study, thus proving C M  ectosom es as a potential 
biom arker source. Ectosom e content m ay not only becom e a source of biom arkers of different disease 
stages, but m ay also contribute to differential diagnosis betw een benign m elanocytic lesions and CM. 
However, while discussing the presence/absence of a particular protein in CM ectosomes, it is necessary 
to acknow ledge the lim itations of protein identification by  shotgun LC-M S/M S. Such proteom ic 
analysis of unseparated , com plex protein m ixture allow s identification of a m uch higher num ber 
of proteins, w hich are not lost during gel band or spot excision. O n the other hand, signals from  
underrepresented peptides m ight be lost among the m ost abundant proteins. The expression level for 
particular proteins m ight have been  low  and n ot detected in a given sam ple replicate in  the present 
study, thus the presence of proteins described as being absent in CM  ectosom es cannot be com pletely 
ruled out.
Finally, it is im portant to notice that the num ber of studies on m elanom a EVs is still very limited. 
M elanom a-derived  grow th regulatory protein (M IA ) and S100B  protein w ere detected in exosom es 
from serum of CM patients and their quantification presented with diagnostic and prognostic potential 
tow ards stage IV  of C M  [41]. M IA  and S100B w ere also identified in ectosom es in the present study, 
thus the population of larger vesicles seem s to have not less potential in terms of biom arker discovery 
research. M ore recently, C resticelli et al. [42] perform ed proteom ic analysis o f sm all and large EVs 
isolated from m elanom a tum ors and confirm ed that m etastatic m elanom a tissues contain a mixture of 
EVs derived from tumor and immune cells. The same group also showed that two mitochondrial inner 
m em brane proteins: cytochrom e c oxidase subunit 2 (M T-CO2) and cytochrom e c oxidase subunit 6C 
(CO X6c) are enriched in  the p lasm a of m elanom a patients as w ell as in tum or tissues-derived EVs 
compared to healthy controls [43]. Studies using hum an tum or tissues are particularly valuable, since 
they fully reflect the com plexity and cellular interactions present w ithin the tum or microenvironment.
Nevertheless, studies based on the proteomic analyses of EVs only create the premise for the large, 
independent and m ulticenter clinical trials that are necessary for the validation of any novel biomarkers. 
D iagnostic and prognostic potential of elevated num bers of ectosom es, or ectosom es bearing certain 
m olecules, depends on the establishm ent of proper isolation protocols. To gain valid inform ation for 
clinical practice, optimal concentrations of uncontam inated vesicle populations w ith maintained native 
form and function are required. O ur results obtained in the present study are prom ising and suggest 
that these investigations should be continued in  the future for C M , a d isease for w hich  effective 
biom arkers are still lacking.
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4. M aterials and M ethods
4.1. M aterials
R P M I1640 GlutaM AX™ -I medium, fetal bovine serum (FBS), M icroBCA Protein Assay kit, Alamar 
Blue cell viability reagent, Acclaim  PepM ap trap (100 C18, 75 gm X 20 m m , 3 gm particle, 100 A pore 
size) and analytical (A cclaim  PepM ap R SLC  C18, 75 gm X 500 m m , 2 gm  particle, 100 A  pore size) 
colum ns w ere all purchased from  Therm o Fisher Scientific (W altham , M A , U SA ). A nti-CD 63 m ouse 
m onoclonal prim ary antibody (clone RFAC4, cat. C BL553), Lum i-LightPLU S W estern B lotting K it 
(including anti-m ouse IgG-H RP secondary antibody), Trypsin-EDTA solution, penicillin/streptomycin 
solution, SpeedBeads™  GE45152105050250 and GE65152105050250, and H EPES buffer w ere obtained 
from Sigm a-Aldrich (St. Louis, M O, USA). M ouse monoclonal primary antibodies for Arf6 (clone 3A-1, 
cat. sc-7971) and HSP70 (clone C92F3A-5, cat. sc-66048) were purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA). Trypsin/Lys-C M ix w as the product of Promega (Madison, W I, USA). All remaining 
chem icals w ere of analytical grade, com m ercially available.
4.2. Cell Lines and Cell Culture Conditions
Four CM  cell lines w ere obtained from the ESTDAB M elanom a C ell Bank (Tubingen, Germ any). 
W M 115 (prim ary) and W M 266-4 (m etastatic) cell lines originated from  the sam e individual 
and represented radial/vertical grow th phase and lym ph node m etastasis, respectively [44]. Prim ary 
W M 793 cell line, representing vertical grow th phase [45], and W M 1205Lu, a m etastatic variant of 
W M 793 cells obtained from lung m etastasis, were also used [46]. Cells w ere m aintained in RPM I 1640 
m edium  w ith  G lutaM A X-I, supplem ented w ith  10% FBS, penicillin  (100 unit/mL) and streptom ycin 
(100 gg/mL). C ells w ere grow n in m onolayers in a 5%  C O 2 atm osphere at 37  °C  in a hum idified 
incubator and passaged after reaching approxim ately 80% confluence.
4.3. Isolation o f  Ectosomes and A ssessm ent o f  the Purity o f  the Ectosome Samples
Sub-confluent cells were cultured for 24 h in serum-free media. Conditioned media were collected 
and subjected to sequential centrifugation steps. After centrifugations at 400X g  (5 min, 4 °C), 4000X g  
(20 min, 4° C) and 7000X g  (20 m in, 4 °C), remaining cells and cellular debris were pelleted and discarded, 
w hereas supernatants w ere collected for ectosom e isolation. A fter final centrifugation at 18,000X g  
(20 min, 4 °C), ectosomes w ere pelleted and resuspended in ice-cold PBS. A more detailed description of 
a centrifugation protocol and theoretical model w ith derived equations are included in Supplementary 
M aterials D ata 3.
The purity of the obtained sam ples w as verified by  transm ission electron m icroscopy (TEM ) as 
previously described [47] as w ell as by  N anoparticle Tracking A nalysis (NTA). NTA m easurem ents 
w ere perform ed on N anoSight LM  10 (M alvern Panalytical) equipped w ith  a 405 nm  laser. For NTA 
analysis, 10 gL of each ectosome sample was diluted to 2 mL with filtered PBS. The measurement time 
w as set at 30 s and five independent records w ere collected for each sam ple. Results w ere analyzed 
using NTA 3.1. softw are and calculated according to the dilutions used. The m ean results ± SD w ere 
presented on graphs.
Additionally, W estern blot (WB) analysis of EV markers was performed. For this purpose, for each 
CM  cell line, w hole-cell protein extracts (prepared as described in [47] ) and ectosom e sam ples (50 gg 
of proteins according to M icroBCA method) were separated on 10% SDS-PAGE stain-free precast gels 
in reducing conditions, and transferred to the PVDF m em brane. The purity of ectosom e sam ples was 
assessed w ith  the use of anti-C D 63 (1:2000), anti-H SP70 (1:2000) and anti-A RF6 (1:500) antibodies. 
A fter 1 h  incubation w ith  prim ary antibodies, anti-m ouse IgG -H RP (1:400) w as used as a secondary 
antibody M arkers were detected using chem ilum inescent substrates for HRP and ChemiDoc Imaging 
System  (Bio-Rad).
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4.4. LC-M S/M S Proteomics
Ectosom e lysis, sam ple preparation for m ass spectrom etric analysis, LC-MS/MS, and analysis of 
proteom ic data w ere perform ed as described below  and in [48] .
4.4.1. Ectosom e Lysis
The ectosom e pellets w ere w ashed three tim es w ith  PBS and suspended in 50 gL of lysis buffer 
(100 m M  Tris-H Cl pH  7.6, 1% SD S). Lysates w ere sonicated w ith  Bioruptor U C D -200 (D iagenode, 
Seraing, Belgium ) for 20 m in at high intensity  (320 W, 30 s/30 s on/off). N ext, the sam ples w ere 
denatured at 95 °C  under strong agitation for 5 m in and centrifuged at 20 ,000x g  for 10 m in at 20 °C.
Proteins were precipitated by adding one volum e of trichloroacetic acid to four volum es of the sample. 
A fter overnight incubation at -2 0  °C sam ples w ere spun at 10,000x g  for 15 m in at 10 °C and w ashed 
two tim es w ith ice-cold acetone. The pellets w ere resuspended in 100 gL of 10 m M  H EPES pH 8.5.
4.4.2. Sam ple Preparation for M ass Spectrom etric Analysis
The sam ples w ere prepared using param agnetic bead technology based  on the Single-Pot 
Solid-Phase-Enhanced Sam ple Preparation (SP3) [49]. G E45152105050250 and G E65152105050250 
SpeedBeads™  mixed in a ratio 1:1 were used. The proteins were reduced w ith dithiothreitol, alkylated 
w ith iodoacetam ide and digested w ith Trypsin/Lys-C Mix.
4.4.3. Liquid C hrom atography and Tandem M ass Spectrom etry (LC-MS/MS)
Peptides w ere analyzed using an  U ltiM ate 3000 R SLC nano System  coupled w ith  a Q -Exactive 
m ass spectrom eter (Therm o Fisher Scientific) w ith  D PV-550 D igital PicoView  nanospray source 
(N ew  O bjective). The sam ple w as loaded onto a trap colum n (A cclaim  PepM ap 100 C18, 75 gm x  
20 m m , 3 gm  particle, 100 A pore size) in 2%  acetonitrile w ith  0.05%  TFA at a flow  rate of 5 gL/min 
and further resolved on an  analytical colum n (A cclaim  PepM ap R SLC  C18, 75 gm  x  500 m m , 2 gm 
particle, 100 A  pore size) w ith  a 90 m in grad ient from  2%  to 40%  acetonitrile in 0.05%  form ic acid 
at a flow  rate o f 200 nL/min. The Q -Exactive w as operated in a data-dependent m ode using the top 
eight method. Full-scan M S spectra were acquired with a resolution of 70,000 at m/z 200 w ith automatic 
gain control (A G C target) of 1 x  10-6 . The MS/MS spectra w ere acquired w ith  a resolution of 35,000 
at m/z 200 w ith  an A G C  target of 3 x  10-6 . The m axim um  ion accum ulation tim es for the full M S 
and the MS/MS scans were 120 ms and 110 ms, respectively. Peptides were dynam ically excluded from 
fragm entation w ithin 30 s. Biological replicates w ere m easured tw ice and searched together.
4.4.4. Analysis of Proteom ic Data
The RAW files were processed by the Proteome Discoverer platform (v.1.4, Thermo Fisher Scientific) 
and searched against the SwissProt database w ith Homo sapiens taxonom y restriction (release February 
2019, 20418 sequences) u sing a locally  installed M A SC O T search engine (v. 2 .5.1, M atrix Science). 
The follow ing param eters w ere applied: fixed m odification, cysteine carbam idom ethylation; variable 
m odifications, m ethionine oxidation and protein N -term inal acetylation; the peptide m ass tolerance, 
10 ppm ; fragm ent m ass tolerance, 20 m m u. O nly tryptic peptides w ith  up to one m issed cleavage 
w ere considered. Target D ecoy PSM  V alidator w as applied w ith  the m axim um  false d iscovery rate 
(FDR) for peptides set to 0.01. The raw data w ere deposited to the Proteom eXchange Consortium  via 
the M assIVE repository w ith the dataset identifier PXD017366.
4.5. Bioinform atic A nalysis
Proteins identified by both biological repetitions of ectosome samples and w ith at least two peptides 
w ere chosen m anually to create the final protein lists. Venn diagram s, including Vesiclepedia protein 
overlap, and gene ontology (GO) analysis, with regard to the cellular com partm ent, molecular function 
and biological processes w ere perform ed w ith  the use of FunR ich 2.0 softw are w ith  protein U niProt
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(release 2019_11) database as a reference. For each GO term , six categories w ith the highest statistical 
significance of protein enrichm ent w ithin  the given category  (calculated as -log10(p -valu e)) w ere 
presented on graphs. Additionally, the percentage and num ber of proteins of selected cancer-related 
categories w ith p value < 0.001 were compared between ectosome sam ples from prim ary and metastatic 
cells. Entire G O  data are provided in Supplem entary  M aterials D ata 4. Interaction diagram s from  
Supplem entary M aterials D ata 2 w ere prepared w ith the use of https://string-db.org/ Version: 11.0.
4.6. W ound H ealing A ssay
W M 115 and W M 793 C M  cells w ere cultured to confluence on 6-w ell plates. Subsequently, 
the cell-coated surface was scraped w ith a 200 gL pipette tip and two different doses (30 gg and 60 gg 
of proteins) of ectosom es w ere added for 18 h of incubation. Each w ound w as photographed in 10 
separate fields im m ediately  after scraping (0 h) and after 18 h. The average percentage of w ound 
closure w as evaluated by  m ultiple m easurem ents of the w ound diam eter using Z eiss A xioVision 
Rel.4.8 im age analysis softw are and calculated as follows:
initial w ound diam eter (0 h) -  w ound diam eter after (18 h)
w ound closure = -------------------------------------------------------------- -——-------------------------
initial w ound diam eter (0 h)
Results w ere standardized in relation to the untreated control (taken as 1).
4.7. A lam ar Blue Cell Viability A ssay
W M 115 and W M 793 CM cells were seeded onto 96-well plates at the density of 1 X 104 cells/100 gL. 
The next day, a serum -free m edium  w as added and cells were incubated w ith two doses of ectosom es 
(30 gg and 60 gg of proteins). After 18 h of incubation, 10% of Alam ar Blue reagent was added to each 
w ell and after 2 h  fluorescence intensity  w as m easured at 560/595 nm . Results w ere standardized in 
relation to the untreated control (taken as 1).
4.8. Statistical Analysis
Three repetitions of Alam ar Blue and w ound healing assays were performed for each experimental 
setting. Analysis of variance (one-w ay ANOVA) and post-hoc Tukey's test w ere later perform ed with 
the use of Statistica 12 softw are to test for statistically significant differences w ith p  value < 0.05.
Supplementary Materials: Supplementary materials can be found at 'http://www.mdpi.com/1422-0067/21/8/2934/ 
s1. LC-MS/MS data are available via ProteomeXchange with identifier PXD017366.
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